Bicalutamide (Casodex) has been around a long time...Two newer drugs, Zytiga and Xtandi both work the same way but MUCH better and more effective...But these drugs are only used after a patient becomes hormone refractory and are seldom if ever used as a primary treatment mainly because insurance companies won't pay for that "experimental" use of these very expensive drugs..If Zytiga and Xtandi cost $50 a month, NOBODY would still be using Casodex....
Not to drift this thread further off course, but this is interesting, Pfizer is trying to gain approval for non-metastatic use of Xtandi
. They see that as the holy grail, not to lower their pricing, but to make good their $14 B bet on the drug. I wouldn't look for the price to go down anytime soon!
From the article:And besides, “as we've said all along, the real critical pivot point for that deal is the non-metastatic, the earlier stage prostate cancer,” CFO Frank D’Amelio added.
“We remain confident in our ability to get approval for those indications,” he said.
Bx: 6/12 pos, G9=5+4 (80%, 60%), 4+5 (2@100%, 80%, 10%), PNI+
cT3a (3T mpMRI: Bilateral EPE, NVB+, SV-, LN-)
Date PSA fPSA
9/12 4.1 15%
3/13 5.2 12% PCA3=31
IGRT by IMRT, 44 done 8/28/13: 50.4 Gy pelvic nodes, 79.2 Gy prostate
ADT2 3 yrs: Lupron/Casodex, ended 3/16
Post: (age now 59)
PSA <0.1 : 8/13 - 5/16; rising - 0.2-8/16, 0.5-12/16, 0.7-3/17, TBD-5/17
Post Edited (Redwing57) : 5/12/2017 6:14:38 PM (GMT-6)